Streetbeat News

Price Targets

LMND

Morgan Stanley analyst Michael Phillips initiates coverage on Lemonade (NYSE:LMND) with an Underweight rating and a price target of $14.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:44 am

ACGL

Morgan Stanley analyst Michael Phillips initiates coverage on Arch Capital Group (NASDAQ:ACGL) with an Overweight rating and a price target of $92.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:42 am

ATMU

Bank of America Securities analyst Andrew Obin initiates coverage on Atmus Filtration Techs (NYSE:ATMU) with a Buy rating and a price target of $25.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:41 am

PFGC

Morgan Stanley analyst John Glass downgraded Performance Food Gr (NYSE:PFGC) from Overweight to Equal-Weight and lowered the price target from $74 to $66.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:26 am

CAR

Morgan Stanley analyst Adam Jonas upgraded Avis Budget Gr (NASDAQ:CAR) from Equal-Weight to Overweight and raised the price target from $182 to $230.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:25 am

USFD

Morgan Stanley analyst John Glass upgraded US Foods Hldg (NYSE:USFD) from Equal-Weight to Overweight and raised the price target from $46 to $54.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:23 am

RYTM

Needham analyst Joseph Stringer reiterates a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and maintains a $32 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:19 am

USAU

HC Wainwright & Co. analyst Heiko Ihle maintains a Buy rating on U.S. Gold (NASDAQ:USAU) and raises the price target from $10.5 to $12.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:18 am

ACLX

Needham analyst Gil Blum reiterated a Buy rating on Arcellx (NASDAQ: ACLX) and maintained a $51 price target.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:17 am

CALT

HC Wainwright & Co. analyst Edwin Zhang initiates coverage on Calliditas Therapeutics (NASDAQ:CALT) with a Buy rating and a price target of $60.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 10:16 am